Division of Haematology

1.

Tóthfalusi, D., Dobó, B., Borics, F., Pinczés, L. I., Illés, Á., Miltényi, Z.: Impact of Comorbidities on Prognosis and Treatment Outcomes in Elderly Patients with Hodgkin Lymphoma.
Clinics and Practice. 15 (1), 1-16, (article identifier: 15), 2025.

doi DEA Scopus

Journal metrics:

Q3 Medicine (miscellaneous) (2023)

2.

Kiss, E., Simon, Z., Illés, Á., Jóna, Á.: Prognostic Significance of Interim PET/CT in the First-Line Treatment of Follicular Lymphoma Patients, a Single-Center Experience.
Cancers (Basel). 17 (1), 1-10, (article identifier: 73), 2025.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research (2023)

Q1 Oncology (2023)

3.

Tordai, A., Tóth, R., Marton, I., Fődi, É., Simon, Z.: A Belügyminisztérium egészségügyi szakmai irányelve a várandósgondozás és a szülészeti betegellátás klinikai transzfuziológiai vonatkozásairól.
Eü. Közl. 74 (9), 1527-1543, 2024.

DEA

4.

Gergely, L.: A CAR-T-sejtes kezelések immunológiai mellékhatásai.
Immunol. Szle. 16 (4), 58-64, 2024.

DEA

5.

Obajed, A. A. O., Pfliegler, G., Magyari, F., Borics, F., Pinczés, L. I., Illés, Á., Brúgós, B.: A Case Report of Hyperhemolytic Syndrome in Sickle Cell Disease, with a Special Focus on Avoiding the Use of Transfusions.
Thalass. Rep. 14 (1), 18-25, 2024.

doi DEA WoS

6.

Méhes, G., Mokánszki, A., Ujfalusi, A., Hevessy, Z., Miltényi, Z., Gergely, L., Bedekovics, J.: Acute Erythroid Leukemia Post-Chemo-Radiotherapy and Autologous Stem Cell Transplantation Due to Multiple Myeloma: tracing the Paths to Leukemic Transformation.
Int. J. Mol. Sci. 25 (14), 1-12, (article identifier: 8003), 2024.

doi DEA WoS Scopus

Journal metrics:

Q2 Catalysis (2023)

Q1 Computer Science Applications (2023)

D1 Inorganic Chemistry (2023)

Q1 Medicine (miscellaneous) (2023)

Q2 Molecular Biology (2023)

D1 Organic Chemistry (2023)

Q1 Physical and Theoretical Chemistry (2023)

D1 Spectroscopy (2023)

7.

Kenyeres, A., Kiss, E., Simon, Z., Illés, Á., Jóna, Á.: Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma.
J. Int. Med. Res. 52 (2), 1-10, 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Biochemistry (2023)

Q3 Biochemistry (medical) (2023)

Q4 Cell Biology (2023)

Q3 Medicine (miscellaneous) (2023)

8.

Brúgós, B., Simon, Z., Zsigmond Soós, I., Illés, Á.: A hideg agglutinin betegség diagnosztikája és ellátási gyakorlata.
Hematol. Trasnzfuziol. 57 (3), 209-217, 2024.

doi DEA

9.

Bíró, K., Ujhelyi, Z., Schlammadinger, Á., Molnárné Rázsó, K., Buchholcz, G., Boda, Z.: Antitrombin-III-deficites gravidák - kezelési lehetőségek.
Gyogyszereszet. 68 (2), 62-66, 2024.

DEA

10.

Gulyás, A., Pinczés, L. I., Mátyus, J., Végh, E., Bedekovics, J., Tóth, J., Barna, S., Hunya, Z., Szabó, I. L., Gazdag, A., Illés, Á., Magyari, F.: Case report: targeted treatment strategies for Erdheim-Chester disease.
Front Oncol. 14, 1-6, (article identifier: 1305518), 2024.

doi DEA WoS Scopus

Journal metrics:

Q2 Cancer Research (2023)

Q2 Oncology (2023)

11.

Batár, P., Alizadeh, H., Rokszin, G., Abonyi-Tóth, Z., Demeter, J.: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.
Pathol. Oncol. Res. 30, 1-11, (article identifier: 1611497), 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Cancer Research (2023)

Q2 Medicine (miscellaneous) (2023)

Q2 Oncology (2023)

Q2 Pathology and Forensic Medicine (2023)

12.

Lahmer, T., Salmanton-García, J., Marchesi, F., Pinczés, L. I., Cornely, O. A., Pagano, L., EPICOVIDEHA registry: Correction: Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey.
Infection. 52 (3), 1191-1194, 2024.

doi DEA Scopus

13.

Batár, P., Alizadeh, H., Rokszin, G., Abonyi-Tóth, Z., Demeter, J.: Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.
Pathol. Oncol. Res. 30, 1-2, (article identifier: 1611758), 2024.

doi DEA WoS Scopus

14.

Salmanton-García, J., Marchesi, F., Farina, F., Magyari, F., Pinczés, L. I., Rahimli, L., Cornely, O. A., Pagano, L., EPICOVIDEHA registry: Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022.
eClinicalMedicine. 71, 1-20, (article identifier: 102553), 2024.

doi DEA Scopus

Journal metrics:

D1 Medicine (miscellaneous) (2023)

15.

Aiello, T. F., Salmanton-García, J., Marchesi, F., Magyari, F., Pinczés, L. I., Cornely, O. A., Garcia-Vidal, C., Pagano, L., EPICOVIDEHA Study group: Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry.
Haematologica. [Epub ahead of print], 2024.

doi DEA

Journal metrics:

D1 Hematology (2023)

16.

Brúgós, B., Simon, Z., Méhes, G., Illés, Á., Pfliegler, G.: Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary.
Pathol. Oncol. Res. 30, 1-10, (article identifier: 1611785), 2024.

doi DEA WoS

Journal metrics:

Q3 Cancer Research (2023)

Q2 Medicine (miscellaneous) (2023)

Q2 Oncology (2023)

Q2 Pathology and Forensic Medicine (2023)

17.

Bicskó, R. R., Illés, Á., Hevessy, Z., Ivády, G., Kerekes, G., Méhes, G., Csépány, T., Gergely, L.: Eculizumab Treatment of Massive Hemolysis Occurring in a Rare Co-Existence of Paroxysmal Nocturnal Hemoglobinuria and Myasthenia Gravis.
Hematol Rep. 16 (2), 255-259, 2024.

doi DEA WoS Scopus

Journal metrics:

Q4 Hematology (2023)

18.

Németh, R., Bicskó, R. R., Illés, Á., Gergely, L.: Epstein-Barr-vírus által indukált hemolízis diffúz nagy B-sejtes limfómában.
Hematol. Trasnzfuziol. 56 (4), 194-198, 2024.

doi DEA

19.

Bedekovics, J., Madarász, K., Mokánszki, A., Deliné Molnár, S., Mester, Á., Miltényi, Z., Méhes, G.: Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies - Interpretive challenges and potential field of applications.
Histopathology. [Epub ahead of print], 2024.

doi DEA Scopus

Journal metrics:

D1 Pathology and Forensic Medicine (2023)

Q1 Histology (2023)

Q1 Medicine (miscellaneous) (2023)

20.

Roboz, G. J., Sanz, G., Griffiths, E. A., Yee, K., Kantarjian, H., Récher, C., Byrne, M. T., Patkowska, E., Kim, H. J., Thomas, X., Moors, I., Stock, W., Illés, Á., Fenaux, P., Miyazaki, Y., Yamauchi, T., O'Connell, C. L., Hao, Y., Keer, H. N., Azab, M., Döhner, H.: Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Blood Adv. 8 (8), 2020-2029, 2024.

doi DEA WoS Scopus

Journal metrics:

D1 Hematology (2023)

21.

Pratz, K. W., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Döhner, H., Recher, C., Fiedler, W., Yamamoto, K., Wang, J., Yoon, S. S., Wolach, O., Yeh, S. P., Leber, B., Esteve, J., Mayer, J., Porkka, K., Illés, Á., Lemoli, R. M., Turgut, M., Ku, G., Miller, C., Zhou, Y., Zhang, M., Chyla, B., Potluri, J., DiNardo, C. D.: Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Am. J. Hematol. 99 (4), 615-624, 2024.

doi DEA WoS Scopus

Journal metrics:

D1 Hematology (2023)

22.

László, T., Kotmayer, L., Fésüs, V., Hegyi, L., Gróf, S., Nagy, Á., Kajtár, B., Balogh, A., Weisinger, J., Masszi, T., Nagy, Z., Farkas, P., Demeter, J., Istenes, I., Szász, R., Gergely, L., Sulák, A., Borbényi, Z., Lévai, D., Schneider, T., Pettendi, P., Bodai, E., Szerafin, L., Rejtő, L., Bátai, Á., Dömötör, M. Á., Sánta, H., Plander, M., Szendrei, T., Hamed, A., Lázár, Z., Pauker, Z., Radványi, G., Kiss, A., Körösmezey, G., Jakucs, J., Dombi, P. J., Simon, Z., Klucsik, Z., Gurzó, M., Tiboly, M., Vidra, T., Ilonczai, P., Bors, A., Andrikovics, H., Egyed, M., Székely, T., Masszi, A., Alpár, D., Matolcsy, A., Bödör, C.: Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.
The Journal of Pathology CR. 10 (1), 1-12, (article identifier: 351), 2024.

doi DEA WoS Scopus

Journal metrics:

D1 Pathology and Forensic Medicine (2023)

23.

Ghansah, H., Orbán-Kálmándi, R. A., Bekéné Debreceni, I., Katona, É., Rejtő, L., Váróczy, L., Lóczi, L., Laat, B. d., Huskens, D., Kappelmayer, J., Bagoly, Z.: Low factor XIII levels and altered fibrinolysis in patients with multiple myeloma.
Thromb. Res. 234, 12-20, 2024.

doi DEA WoS Scopus

Journal metrics:

Q1 Hematology (2023)

24.

Gupta, V., Oh, S. T., Devos, T., Dubruille, V., Catalano, J., Somervaille, T. C. P., Platzbecker, U., Giraldo, P., Kosugi, H., Sacha, T., Mayer, J., Illés, Á., Ellis, C., Wang, Z., Gonzalez Carreras, F. J., Strouse, B., Mesa, R.: Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Leuk. Lymphoma. 65 (7), 965-977, 2024.

doi DEA WoS Scopus

Journal metrics:

Q3 Cancer Research (2023)

Q2 Hematology (2023)

Q2 Oncology (2023)

25.

Woyach, J. A., Jones, D., Jurczak, W., Robak, T., Illés, Á., Kater, A. P., Ghia, P., Byrd, J. C., Seymour, J. F., Long, S., Mohamed, N., Benrashid, S., Lai, T. H., Jesus, G. D., Lai, R., Bruin, G. d., Rule, S., Munugalavadla, V.: Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib.
Blood. [Epub ahead of print], 2024.

doi DEA Scopus

Journal metrics:

D1 Biochemistry (2023)

D1 Cell Biology (2023)

D1 Hematology (2023)

D1 Immunology (2023)

Division of Haematology

Publication list